Amicus Therapeutics (NASDAQ:FOLD) is scheduled to be posting its quarterly earnings results before the market opens on Monday, November 5th. Analysts expect Amicus Therapeutics to post earnings of ($0.27) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.33). Amicus Therapeutics had a negative return on equity of 53.45% and a negative net margin of 460.04%. The business had revenue of $21.31 million for the quarter, compared to analysts’ expectations of $18.92 million. On average, analysts expect Amicus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of FOLD stock opened at $11.85 on Friday. Amicus Therapeutics has a one year low of $10.33 and a one year high of $17.62. The company has a current ratio of 10.88, a quick ratio of 10.73 and a debt-to-equity ratio of 0.30.
A number of equities analysts have issued reports on the company. Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a report on Tuesday, July 10th. ValuEngine cut Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 19th. BidaskClub cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 28th. Chardan Capital cut Amicus Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $18.00 to $15.00 in a report on Friday, August 17th. Finally, Cowen restated a “buy” rating and set a $31.00 price target on shares of Amicus Therapeutics in a report on Friday, October 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $19.50.
In other Amicus Therapeutics news, major shareholder Perceptive Advisors Llc purchased 20,000 shares of the business’s stock in a transaction on Monday, September 24th. The shares were purchased at an average cost of $12.45 per share, for a total transaction of $249,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO William D. Baird III sold 10,000 shares of the stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $12.23, for a total value of $122,300.00. Following the transaction, the chief financial officer now owns 127,622 shares in the company, valued at $1,560,817.06. The disclosure for this sale can be found here. Insiders have acquired a total of 620,000 shares of company stock worth $7,505,000 over the last 90 days. Company insiders own 2.90% of the company’s stock.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Further Reading: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.